Annual report pursuant to Section 13 and 15(d)

Note 1 - Description of Business

v3.20.1
Note 1 - Description of Business
12 Months Ended
Dec. 31, 2019
Notes  
Note 1 - Description of Business

NOTE 1 – DESCRIPTION OF BUSINESS

 

The business model of ZIVO Bioscience, Inc. and Subsidiaries (Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., Wellmetrix, LLC (fka WellMetris, LLC), and Zivo Biologic, Inc., (collectively the “Company”) is as follows: 1) to derive future income from licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal, human and dietary supplement and medical food manufacturers, and 2) developing, manufacturing, marketing, and selling tests that the Company believes will allow people to optimize their health and identify future health risks.